文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

HA-330血液吸附治疗需大剂量去甲肾上腺素的脓毒性休克:多中心随机对照试验(CLEANSE)

HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE).
PubMed 文献 · Crit Care · 2026-06-11
一句话结论在需去甲肾上腺素≥0.2 mcg/kg/min的脓毒性休克患者中,HA-330辅助血液吸附未显著降低28天死亡率(58% vs 44%,RR 0.76,95%CI 0.54-1.07,P=0.16)。

这项在泰国两家三级中心进行的多中心随机对照试验,纳入需去甲肾上腺素≥0.2 mcg/kg/min的脓毒性休克患者,1:1分配至标准治疗组(ST组)或标准治疗加两次3小时HA-330血液吸附组(HA组)。因招募缓慢和资金限制,试验在第二次预设中期分析时提前终止,未达到计划样本量206例,实际纳入128例(ST组65例,HA组63例)。28天死亡率ST组58%(38/65)vs HA组44%(28/63),相对风险0.76(95%CI 0.54-1.07,P=0.16),风险比0.68(95%CI 0.44-1.07,P=0.09),无统计学显著差异。器官支持无天数、休克逆转、血管活性药剂量及炎症标志物均无显著差异,两组均未报告严重不良事件。

要点

  • 在需去甲肾上腺素≥0.2 mcg/kg/min的脓毒性休克患者中,HA-330辅助血液吸附未显著降低28天死亡率:ST组58%(38/65)vs HA组44%(28/63),RR 0.76(95%CI 0.54-1.07,P=0.16)。
  • 28天死亡率风险比0.68(95%CI 0.44-1.07,P=0.09),未达统计学显著。
  • 器官支持无天数、休克逆转、血管活性药剂量及炎症标志物均无显著差异。
  • 两组均未报告严重不良事件。
  • 试验因招募缓慢和资金限制提前终止,未达到计划样本量206例,实际纳入128例。

适用人群与场景

  • 纳入标准:脓毒性休克,需去甲肾上腺素≥0.2 mcg/kg/min。
  • 研究在泰国两家三级中心进行。

处置流程与药物剂量

  • 标准治疗组(ST组):仅接受标准治疗。
  • 血液吸附组(HA组):标准治疗加用HA-330细胞因子吸附器进行两次3小时血液吸附 sessions。
  • 去甲肾上腺素剂量:入组时需≥0.2 mcg/kg/min。

研究设计与关键结果

  • 研究类型:多中心随机对照试验,在泰国两家三级中心进行,1:1分配至ST组或HA组。
  • 样本量:计划206例,实际纳入128例(ST组65例,HA组63例);因招募缓慢和资金限制在第二次预设中期分析时提前终止。
  • 人群:脓毒性休克需去甲肾上腺素≥0.2 mcg/kg/min的患者,中位年龄67岁,基线特征基本可比。
  • 主要终点:28天死亡率ST组58%(38/65)vs HA组44%(28/63),相对风险0.76(95%CI 0.54-1.07,P=0.16);风险比0.68(95%CI 0.44-1.07,P=0.09)。
  • 次要终点:器官支持无天数、休克逆转、血管活性药剂量及炎症标志物均无显著差异。
  • 事后分析:调整IL-6(对数转换)和第0小时VIS的Cox模型,28天死亡率风险比0.62(95%CI 0.39-0.97,P=0.037)。
  • 不良事件:两组均未报告严重不良事件。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验。
  • 试验注册:ClinicalTrials.gov NCT05136183,注册日期2021年11月29日。
  • 局限:试验因招募缓慢和资金限制提前终止,未达到计划样本量206例。

对床旁实践的改变

  • 对于脓毒性休克需去甲肾上腺素≥0.2 mcg/kg/min的患者,HA-330辅助血液吸附未显著降低28天死亡率,未改变标准治疗。
  • 事后分析提示调整IL-6和VIS后28天死亡风险比0.62(95%CI 0.39-0.97,P=0.037),但原文结论为未显著降低28天死亡率,该事后分析结果需进一步研究。

指南或共识出处

  • CLEANSE试验,ClinicalTrials.gov NCT05136183,注册日期2021年11月29日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inflammatory cytokines play a pivotal role in septic shock, driving tissue injury and circulatory failure. Hemoadsorption has been proposed as an extracorporeal strategy that removes inflammatory mediators. Patient selection and treatment timing may be integral to clinical benefit.

OBJECTIVES: To determine whether adjunctive hemoadsorption with the HA-330 cytokine adsorber reduces 28-day mortality in patients with septic shock requiring high-dose vasopressors, compared with standard treatment alone.

METHODS: This multicenter, randomized controlled trial enrolled patients with septic shock requiring norepinephrine ≥ 0.2 mcg/kg/min at two tertiary care centers in Thailand. Participants were assigned 1:1 to standard treatment alone (ST group) or standard treatment with two 3-hour sessions of hemoadsorption using HA-330 (HA group). The primary outcome was 28-day mortality. The trial was terminated early at the second pre-planned interim analysis due to slow recruitment and funding constraints before reaching the planned sample size of 206 participants.

RESULTS: A total of 128 participants were enrolled; 65 were assigned to the ST group and 63 to the HA group. The median age was 67 years, and baseline characteristics were largely comparable between groups. By day 28, 38 of 65 (58%) participants in the ST group and 28 of 63 (44%) in the HA group had died (relative risk, 0.76; 95% CI, 0.54-1.07; P = 0.16; hazard ratio, 0.68; 95% CI, 0.44-1.07; P = 0.09). No significant differences were observed in organ support-free days, shock reversal, vasopressor doses, or inflammatory markers. In a post-hoc Cox model adjusted for IL-6 (log-transformed) and VIS at hour 0, the hazard ratio for 28-day mortality was 0.62 (95% CI, 0.39-0.97; P = 0.037). No serious adverse events were reported in either group.

CONCLUSIONS: In this randomized trial which was terminated early, adjunctive hemoadsorption with HA-330 in patients with septic shock requiring high-dose vasopressors did not statistically reduce 28-day mortality.

TRIAL REGISTRATION: ClinicalTrials.gov (NCT05136183); registered November 29, 2021.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Wongtirawit N, Inyu W, Prajantasen U, et al. HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE). Crit Care. 2026. PMID: 42277846. doi:10.1186/s13054-026-06121-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。